Exelixis Q3 2016 Financial Results

Exelixis presented third-quarter 2016 financial results covering commercial progress of CABOMETYX and COMETRIQ oncology drugs, development updates on cabozantinib pipeline programs, and financial guidance. The presentation includes forward-looking statements regarding regulatory milestones, collaboration partner activity, and cash position expectations through year-end 2016.